Statins may provide a compounded effect on ART by decreasing cholesterol levels thus decreasing de novo androgen synthesis and tumor cell viability. We investigated the clinical efficacy of concurrent statin use on outcomes of patients with mCRPC taking ART.
A single-institution retrospective analysis of patients with mCRPC receiving ART from 2010 to 2021 was performed. Our primary outcome was PSA progression free survival (PFS), and our secondary outcomes were overall survival (OS). Patient characteristics were collected in addition to ART treatment course, statin treatment, and survival outcomes. Cox proportional hazards regression model was used to estimate hazard ratios (HR) for OS and PSA PFS and multivariable logistic regression to determine risk factors.
153 patients with mCRPC treated with ART were included. A total of 67 patients (43.8%) received concurrent statins. Median PSA PFS was 20.4 months for patients that received statins versus 15.3 months for patients who did not receive statins. Median OS was 45.1 months for patients who received concurrent statins versus 29.7 months for patients who did not. On univariate and multivariate survival analyses, there was no statistically significant difference between groups for PSA PFS (HR 0.7; CI 0.44-1.1; P = .123) and OS (HR 0.67; CI 0.42-1.06; P = .089).
Our analysis suggests that statins do not significantly improve clinical outcomes in patients with mCRPC. Ultimately, current understanding remains limited, and prospective studies are needed, but here we provide a cost-effective, timely, and selective preliminary analysis.
Clinical genitourinary cancer. 2024 Sep 24 [Epub ahead of print]
Zakaria Chakrani, Mann Patel, George Mellgard, Stephen McCroskery, Nathaniel Saffran, Nicole Taylor, Bobby C Liaw, Matthew Galsky, William Oh, Che-Kai Tsao, Teja Ganta, Vaibhav Patel
Department of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY., Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ., Department of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY; Department of Medicine, NewYork Presbyterian-Columbia University Irving Medical Center, New York, NY., Department of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY; Icahn School of Medicine at Mount Sinai, Tisch Cancer Center, New York, NY., Department of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY; School of Medicine, New York Medical College, Valhalla, NY., Department of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY; Prostate Cancer Foundation, Santa Monica, CA; School of Medicine, New York Medical College, Valhalla, NY., Department of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY; Arvinas Inc, New Haven, CT. Electronic address: vaibhav.patel@mountsinai.org.